We are live on ! Find out more

Replimune Group

REPL

Market cap $1.65B

17.39 USD

+1.33

8.28%

At close Updated Oct 29, 4:00 PM EDT

Pre-market

After hours

17.40

+0.01

0.06%

1 day

8.28%

5 days

45.89%

1 month

33.77%

3 months

221.44%

6 months

630.67%

Year to date

95.39%

1 year

70.32%

5 years

-41.07%

10 years

14.71%

About: Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Employees: 465

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 6.1%

Neutral 93.2%

Negative 0.7%

The Motley Fool

Replimune: 3 Key Takeaways for Long-Term Investors

Replimune ended the second quarter with $307.8 million in cash. Over 15 institutions wrote prescriptions within 20 business days.

Replimune: 3 Key Takeaways for Long-Term Investors

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Group, Inc. ( REPL ) Q2 2027 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Arleen Goldenberg Sushil Patel - CEO & Director Michelle DiNapoli - Chief Commercial Officer Emily Hill - Chief Financial Officer Conference Call Participants Evan Seigerman - BMO Capital Markets Equity Research Allison Bratzel - Piper Sandler & Co., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Jiale Song - Jefferies LLC, Research Division Mubeen Mosaheb Romy O'Connor - Van Lanschot Kempen NV Presentation Operator Good day, and thank you for standing by. Welcome to the Replimune's Second Quarter Fiscal 2027 Earnings Conference Call.

Replimune Group, Inc. (REPL) Q2 2027 Earnings Call Transcript

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

TUDRIQEV first delivered to patients for advanced melanoma on October 6th More than 15 institutions have prescribed TUDRIQEV Management will host a webcast today at 8:00 a.m. ET WOBURN, Mass.

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

WOBURN, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a commercial stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that it will host a conference call on Wednesday, October 28, 2026, at 8:00 a.m. ET to discuss its financial results and provide corporate update for the fiscal second quarter ended September 30, 2026.

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70. Replimune told investors its RP1 resubmission was a complete response to the FDA's prior deficiency letter and that commercial launch teams stood ready; the agency's April 2026 rejection letter stated the study design concerns it had previously communicated were never addressed, and REPL shares fell to $1.70.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

New class action for Replimune (REPL) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 10/5/2026

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

If you purchased or acquired Replimune securities between October 20, 2025 and April 10, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at [email protected] or by telephone at (212) 355-4648.

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live ReplimuneConnect Plus a comprehensive program that provides dedicated support and resources to help eligible patients access TUDRIQEV in the U.S. now live

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (NASDAQ: REPL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Replimune securities between October 20, 2025 and April 10, 2026, both dates inclusive (the “Class Period”).

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

Important Information Regarding Section 20(a) Individual Liability Claims: CEO Sushil Patel and CFO Emily Hill are named as individual defendants in a securities class action alleging Replimune's RP1 disclosures omitted unresolved FDA study-design concerns. NEW YORK, Oct. 1, 2026 /PRNewswire/ -- SueWallSt alerts investors in Replimune Group, Inc. (NASDAQ: REPL) of a pending securities class action brought on behalf of shareholders who purchased securities between October 20, 2025 and April 10, 2026.

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL

See News Rankings

Price charts implemented using Lightweight Charts™